Sucraid Market Report 2026

Sucraid Market Overview

• The Sucraid market growth in the historic period has been driven by clinical recognition of csid as a distinct disorder, availability of sacrosidase-based therapies • Market expansion is supported by increasing diagnosis rates of csid, rising focus on personalized nutrition management • Growth Driver: Increase In Rare Genetic Disorders Is Driving Growth In The Market • Market Trend: Regulatory Approval Of Sucraid Expands Treatment Options For New Formulations And Manufacturing Processes • North America was the largest region in 2025.

What Is Covered Under Sucraid Market?

Sucraid is a prescription medication that contains the active ingredient sacrosidase, an enzyme that helps break down sucrose (table sugar) into glucose and fructose. It is used primarily for managing congenital sucrase-isomaltase deficiency (CSID), a rare genetic disorder where the body cannot properly digest sucrose and certain other sugars. The main types of clinical indications in sucraid are congenital sucrase-isomaltase deficiency (CSID), chronic diarrhea associated with CSID, and unexplained gastrointestinal symptoms (suspected CSID). It is distributed through hospitals and pharmacies. And catering to various end users, such as pediatric and adult.

What Is The Sucraid Market Growth Forecast?

The growth in the forecast period can be attributed to increasing diagnosis rates of csid, rising focus on personalized nutrition management, expansion of rare disease treatment programs, growing investments in enzyme therapy innovation, improved patient access through specialty pharmacies. Major trends in the forecast period include increasing focus on rare genetic disorder treatments, growing demand for enzyme replacement therapies, expansion of personalized digestive disorder management, rising awareness of csid diagnosis, improved access to prescription enzyme therapies.

Global Sucraid Market Segmentation

1) By Clinical Indication: Congenital Sucrase-Isomaltase Deficiency (CSID), Chronic Diarrhea Associated With CSID, Unexplained Gastrointestinal Symptoms (Suspected CSID) 2) By Distribution Channel: Hospitals, Pharmacies 3) By End User: Pediatric, Adult

What Are The Drivers Of The Sucraid Market?

The increase in rare genetic disorders is expected to propel the growth of the sucraid market going forward. Rare genetic disorders refer to conditions caused by mutations or changes in an individual's DNA and occur infrequently in the general population. The prevalence of genetic disorders can be due to advancements in genetic testing leading to better detection, environmental influences, and, in some cases, lifestyle factors that contribute to mutations in DNA. Sucraid provides essential enzyme replacement therapy for individuals with the rare genetic disorder congenital sucrase-isomaltase deficiency (CSID), enabling them to properly digest sucrose and maltose, which are otherwise indigestible due to a deficiency or absence of the sucrase-isomaltase enzyme. For instance, in May 2024, according to the National Health Service, a UK-based government department, in England, approximately 17,000 people live with sickle cell disease, an inherited blood disorder, with around 250 new cases diagnosed each year. Therefore, the increase in rare genetic disorders drives growth in the sucraid industry. The rising healthcare expenditure is expected to propel the growth of the sucraid market going forward. Healthcare expenditure is the total amount spent on healthcare services and products within a specific time frame, usually measured annually. Rising healthcare expenditure is due to an aging population, increasing prevalence of chronic diseases, advancements in medical technology, higher costs of pharmaceuticals, and the expansion of healthcare access and services. Sucraid is an effective enzyme replacement therapy for congenital sucrase-isomaltase deficiency (CSID) that helps reduce healthcare expenditure by minimizing the need for costly hospitalizations, diagnostic procedures, and long-term complications associated with untreated digestive disorders. For instance, in April 2025, according to the Office for National Statistics, a UK-based government agency reported that provisional estimates show UK healthcare spending reached £317 billion in 2024, growing 6.5% nominally and 2.4% in real terms from 2023. Total long-term care expenditure rose 3.1% in real terms in 2023, primarily due to increased government spending. Therefore, the rising healthcare expenditure is driving growth in the sucraid industry.

Key Players In The Global Sucraid Market

Major companies operating in the sucraid market are QOL Medical LLC

Global Sucraid Market Trends and Insights

The key trend in the sucraid market is obtaining regulatory approvals for new formulations and manufacturing processes, which enhances product availability and patient access. Regulatory approvals refer to the formal authorization granted by governmental or regulatory bodies for a drug, medical device, or treatment to be marketed and used by the public. For instance, in September 2023, QOL Medical LLC., a US-based pharmaceutical company, received Food and Drug Administration (FDA) approval for Sucraid (sacrosidase) in single-use containers, which is specifically designed for patients over 33 pounds (15 kg). This approval addresses previous supply shortages and improves patient access by providing a more convenient dosage form that maintains stability at room temperature for up to three days. The focus on regulatory compliance facilitates the restoration of Sucraid's supply and highlights the importance of innovation in treatment delivery for rare diseases.

Regional Insights

North America was the largest region in the sucraid market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Sucraid Market?

The sucraid market consists of sales of sucraid enzyme supplements, syrups and tablets, and pharmaceuticals for digestive health. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Sucraid Market Report 2026?

The sucraid market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the sucraid industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.